Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYMAKER-U03 Substudy 03A in first-line metastatic clear cell renal cell carcinoma
2023-506838-68-00Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 15
01
Overview
Phase 2, randomised, open-label trial of pembrolizumab, lenvatinib, favezelimab, belzutifan, quavonlimab and 1 more in renal cell carcinoma (RCC) (4 arms), sponsored by Merck & Co. Primary endpoints: Number of participants with one or more dose-limiting toxicities in the safety lead-in phase, Number of participants with one or more adverse events in the safety lead-in phase and 5 more. Started Jan 2024; status: completed.
02
Drugs
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2023-506838-68-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506838-68-00.